|
rs710521
|
|
|
0.740 |
GeneticVariation |
BEFREE |
Genome-wide association studies have confirmed association of TP63C/T rs710521, TERTC/T rs2736098, and SLC14A1C/T rs17674580 gene variants with susceptibility to bladder cancer (BC) in European and White population.
|
25218484 |
2014 |
|
rs710521
|
|
|
0.740 |
GeneticVariation |
BEFREE |
Performing a meta-analysis of 5,695 cases and 40,187 controls including all published studies on rs710521, a convincing association with bladder cancer risk was obtained (OR = 1.18; 95% Cl = 1.12-1.25; P < 0.0001).
|
21063684 |
2010 |
|
rs710521
|
|
|
0.740 |
GeneticVariation |
BEFREE |
We genotyped rs9642880 G>T on 8q24 and rs710521</span> A>G on 3q28 in a two-stage case-control study of bladder cancer to evaluate the association and further examined the expression of MYC.
|
19369583 |
2009 |
|
rs11892031
|
|
|
0.730 |
GeneticVariation |
BEFREE |
Using data on high-risk occupations for 2258 case patients and 2410 control patients from two bladder cancer studies, we observed that three of 16 known or candidate bladder cancer susceptibility variants displayed statistically significant and consistent evidence of additive interactions; specifically, the GSTM1 deletion polymorphism (P interaction ≤ .001), rs11892031 (UGT1A, P interaction = .01), and rs798766 (TMEM129-TACC3-FGFR3, P interaction = .03).
|
26374428 |
2015 |
|
rs11892031
|
|
|
0.730 |
GeneticVariation |
BEFREE |
Results showed that heterogeneity in ORs of tumor categories was not significant for either rs11892031 or rs401681 (p>0.05), indicating that the two SNPs seemingly do not associate with tumor grade and stage of bladder cancer in our study population.
|
25347272 |
2014 |
|
rs17674580
|
|
|
0.730 |
GeneticVariation |
BEFREE |
Genome-wide association studies have confirmed association of TP63C/T rs710521, TERTC/T rs2736098, and SLC14A1C/T rs17674580 gene variants with susceptibility to bladder cancer (BC) in European and White population.
|
25218484 |
2014 |
|
rs17674580
|
|
|
0.730 |
GeneticVariation |
BEFREE |
Overall, seven of the 14 variants were significantly associated with bladder cancer risk (p = 9.763 × 10(-3) for rs9642880 at 8q24.21, p = 3.004 × 10(-3) for rs2294008 at 8q24.3, p = 0.012 for rs798766 at 4p16.3, p = 0.034 for rs1495741 at 8p22, p = 2.306 × 10(-4) for GSTM1, p = 8.507 × 10(-8) for rs17674580 at 18q12.3, p = 7.179 × 10(-4) for rs10936599 at 3q26.2) and the odds ratios (ORs) ranged from 1.13 to 1.65.
|
24740636 |
2014 |
|
rs17674580
|
|
|
0.730 |
GeneticVariation |
BEFREE |
It is speculated that rs17674580, or other sequence variants in LD with it, indirectly modifies UBC risk by affecting urine production.
|
21750109 |
2011 |
|
rs11892031
|
|
|
0.730 |
GeneticVariation |
BEFREE |
In a combined analysis, we identified three new regions associated with bladder cancer on chromosomes 22q13.1, 19q12 and 2q37.1: rs1014971, (P = 8 × 10⁻¹²) maps to a non-genic region of chromosome 22q13.1, rs8102137 (P = 2 × 10⁻¹¹) on 19q12 maps to CCNE1 and rs11892031 (P = 1 × 10⁻⁷) maps to the UGT1A cluster on 2q37.1.
|
20972438 |
2010 |
|
rs10936599
|
|
|
0.720 |
GeneticVariation |
BEFREE |
At the end of the study, we suggested that there may exist an association between a combination of MYNN rs10936599 and TERC rs2293607 polymorphisms and development of bladder cancer in Turkish population.
|
30120764 |
2019 |
|
rs121913483
|
|
|
0.720 |
GeneticVariation |
BEFREE |
PATIENT SUMMARY: We propose that APOBEC-mediated mutagenesis can generate clinically relevant driver mutations even within suboptimal motifs, such as in the case of FGFR3 S249C, one of the most common mutations in bladder cancer.
|
30975452 |
2019 |
|
rs1014971
|
|
|
0.720 |
GeneticVariation |
BEFREE |
SNP rs1014971 was associated with bladder cancer risk, increased APOBEC3B expression, and enrichment with APOBEC-signature mutations in bladder tumors.
|
27643540 |
2016 |
|
rs1495741
|
|
|
0.720 |
GeneticVariation |
BEFREE |
To quantify the association between rs1495741 and the risk of bladder cancer and to estimate the interaction effect of this genetic variant with smoking, we performed a systematic literature review and meta-analysis involving 14,815 cases and 58,282 controls from 29 studies.
|
27495060 |
2016 |
|
rs10936599
|
|
|
0.720 |
GeneticVariation |
BEFREE |
Overall, seven of the 14 variants were significantly associated with bladder cancer risk (p = 9.763 × 10(-3) for rs9642880 at 8q24.21, p = 3.004 × 10(-3) for rs2294008 at 8q24.3, p = 0.012 for rs798766 at 4p16.3, p = 0.034 for rs1495741 at 8p22, p = 2.306 × 10(-4) for GSTM1, p = 8.507 × 10(-8) for rs17674580 at 18q12.3, p = 7.179 × 10(-4) for rs10936599 at 3q26.2) and the odds ratios (ORs) ranged from 1.13 to 1.65.
|
24740636 |
2014 |
|
rs1495741
|
|
|
0.720 |
GeneticVariation |
BEFREE |
Overall, seven of the 14 variants were significantly associated with bladder cancer risk (p = 9.763 × 10(-3) for rs9642880 at 8q24.21, p = 3.004 × 10(-3) for rs2294008 at 8q24.3, p = 0.012 for rs798766 at 4p16.3, p = 0.034 for rs1495741 at </span>8p22, p = 2.306 × 10(-4) for GSTM1, p = 8.507 × 10(-8) for rs17674580 at 18q12.3, p = 7.179 × 10(-4) for rs10936599 at 3q26.2) and the odds ratios (ORs) ranged from 1.13 to 1.65.
|
24740636 |
2014 |
|
rs8102137
|
|
|
0.720 |
GeneticVariation |
BEFREE |
We found that the original GWAS marker rs8102137 represents a group of 47 linked SNPs (with r(2) ≥ 0.7) associated with increased bladder cancer risk.
|
25320178 |
2014 |
|
rs1014971
|
|
|
0.720 |
GeneticVariation |
BEFREE |
In a combined analysis, we identified three new regions associated with bladder cancer on chromosomes 22q13.1, 19q12 and 2q37.1: rs1014971, (P = 8 × 10⁻¹²) maps to a non-genic region of chromosome 22q13.1, rs8102137 (P = 2 × 10⁻¹¹) on 19q12 maps to CCNE1 and rs11892031 (P = 1 × 10⁻⁷) maps to the UGT1A cluster on 2q37.1.
|
20972438 |
2010 |
|
rs8102137
|
|
|
0.720 |
GeneticVariation |
BEFREE |
In a combined analysis, we identified three new regions associated with bladder cancer on chromosomes 22q13.1, 19q12 and 2q37.1: rs1014971, (P = 8 × 10⁻¹²) maps to a non-genic region of chromosome 22q13.1, rs8102137 (P = 2 × 10⁻¹¹) on 19q12 maps to CCNE1 and rs11892031 (P = 1 × 10⁻⁷) maps to the UGT1A cluster on 2q37.1.
|
20972438 |
2010 |
|
rs121913483
|
|
|
0.720 |
GeneticVariation |
BEFREE |
Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer.
|
17384684 |
2007 |
|
rs2042329
|
|
|
0.710 |
GeneticVariation |
BEFREE |
The rs2042329 risk allele was also related to significantly increased expression levels of CWC27 mRNA and protein in bladder cancer tissues from Chinese patients.
|
27206850 |
2016 |
|
rs11543198
|
|
|
0.710 |
GeneticVariation |
BEFREE |
SNP rs8041357, which is in complete linkage disequilibrium (r(2) = 1) with rs11543198, was also associated with bladder cancer risk in Europeans (P = 0.045 for an additive and P = 0.025 for a recessive model), despite much lower minor allele frequency in Europeans (3.7%) compared with the Japanese (22.2%).
|
25281661 |
2015 |
|
rs401681
|
|
|
0.710 |
GeneticVariation |
BEFREE |
Results showed that heterogeneity in ORs of tumor categories was not significant for either rs11892031 or rs401681 (p>0.05), indicating that the two SNPs seemingly do not associate with tumor grade and stage of bladder cancer in our study population.
|
25347272 |
2014 |
|
rs62185668
|
|
|
0.710 |
GeneticVariation |
BEFREE |
Several correlated variants at 20p12, represented by rs62185668, show genome-wide significant association with UBC after combining discovery and replication results (OR = 1.19, P = 1.5 × 10(-11) for rs62185668-A, minor allele frequency = 23.6%).
|
24861552 |
2014 |
|
rs10775480
|
|
|
0.710 |
GeneticVariation |
BEFREE |
Our data suggest that SLC14A1 could be a unique urea transporter in the bladder that has the ability to influence urine concentration and that this mechanism might explain the increased bladder cancer susceptibility associated with rs10775480.
|
23754249 |
2013 |
|
rs2228000
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Meta-analyses corroborated the above results, showing strong association of Ala499Val (OR = 1.54, CI = 1.21-1.97, p = 0.001) but not that of Lys939Gln (OR = 1.13, CI = 0.95-1.34, p = 0.171) with urinary bladder cancer risk.
|
27246180 |
2016 |